当前位置: X-MOL 学术J. Parkinson’s Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Minority Enrollment in Parkinson's Disease Clinical Trials: Meta-Analysis and Systematic Review of Studies Evaluating Treatment of Neuropsychiatric Symptoms.
Journal of Parkinson’s Disease ( IF 5.2 ) Pub Date : 2020-09-04 , DOI: 10.3233/jpd-202045
Daniel G Di Luca 1 , Jacob A Sambursky 1 , Jason Margolesky 1 , Joacir Graciolli Cordeiro 1 , Anthony Diaz 1 , Danielle S Shpiner 1 , Henry P Moore 1 , Carlos Singer 1 , Corneliu Luca 1
Affiliation  

Background:Randomized clinical trials (RCTs) in Parkinson’s disease (PD) have historically enrolled a low number of underrepresented minorities, lessening the generalizability of therapeutic developments. Although there are racial disparities in PD, little is known regarding neuropsychiatric symptoms and other nonmotor manifestations across all races/ethnicities. Objective:To assess minority participation in PD trials evaluating the treatment of neuropsychiatric symptoms and explore underlying reasons. Methods:We systematically searched PubMed and Embase for RCTs with a primary goal of treating neuropsychiatric symptoms in PD patients from 2000-2019. The pooled prevalence and 95% confidence interval (CI) of being white and enrolled in a clinical trial was calculated using the inverse variance method. I-square was calculated as a measure of heterogeneity and meta-regression was used to evaluate temporal trends. Results:We included 63 RCTs with a total of 7,973 patients. In pooled analysis, 11 (17.5%) RCTs reported race/ethnicity. Of studies reporting this data, 5 African American (0.2%), 16 Hispanics (0.64%), and 539 Asians (21.44%) were enrolled. The pooled prevalence of being white in clinical trials was 98% (CI 0.97–0.98, p < 0.001), with 1,908 patients (75.8%). NIH-funded studies were most likely to report racial data when compared to non-NIH trials (p = 0.032). Conclusion:This large pooled analysis found a small percentage of RCTs reporting race/ethnicity when evaluating treatment of neuropsychiatric symptoms in PD. There was a disproportionally high number of white patients when compared to African Americans and Hispanics. More studies are needed to investigate this discrepancy and improve rates of & minority enrollment in PD trials.

中文翻译:

帕金森病临床试验中的少数群体登记:对神经精神症状治疗评估研究的荟萃分析和系统回顾。

背景:帕金森病 (PD) 的随机临床试验 (RCT) 历来招募了少数代表性不足的少数群体,从而降低了治疗发展的普遍性。尽管 PD 存在种族差异,但对所有种族/民族的神经精神症状和其他非运动表现知之甚少。目的:评估少数群体参与评估神经精神症状治疗的 PD 试验并探讨潜在原因。方法:我们系统地搜索了 PubMed 和 Embase 的 RCT,其主要目标是治疗 2000-2019 年 PD 患者的神经精神症状。使用逆方差方法计算白人并参加临床试验的汇总患病率和 95% 置信区间 (CI)。计算 I 方作为异质性的度量,元回归用于评估时间趋势。结果:我们纳入了 63 项 RCT,共 7,973 名患者。在汇总分析中,11 (17.5%) 项 RCT 报告了种族/民族。在报告此数据的研究中,纳入了 5 名非洲裔美国人 (0.2%)、16 名西班牙裔美国人 (0.64%) 和 539 名亚洲人 (21.44%)。临床试验中白人的汇总流行率为 98%(CI 0.97-0.98,p < 0.001),有 1,908 名患者(75.8%)。与非 NIH 试验相比,NIH 资助的研究最有可能报告种族数据(p = 0.032)。结论:这项大型汇总分析发现,在评估 PD 中神经精神症状的治疗时,有一小部分 RCT 报告了种族/民族。与非裔美国人和西班牙裔美国人相比,白人患者的数量不成比例。
更新日期:2020-09-05
down
wechat
bug